HGSI Human Genome Sciences, Inc. (MM)

LONDON--Pharmaceutical company GlaxoSmithKline PLC (GSK.LN) Friday confirmed that it has received a renewed invitation from Human Genome Sciences (HGSI) to participate in its strategic alternatives review process which started in April, and said it is continuing with its tender for the company.

MAIN FACTS:

-GSK continues to believe that participation in the process is unnecessary given the company's offer is not conditioned on due diligence or financing and can be completed expeditiously.

-Shares at 1405 GMT down 0.7%, at 1,449 pence valuing the company at GBP72.6 billion.

-Write to Ed Ballard at ed.ballard@dowjones.com